Navigation Links
Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Apr 18, 2007 - Gemin X today announced the presentation of positive preclinical data from a study of its lead compound, GX15-070 (obatoclax), in infant acute lymphoblastic leukemia (ALL). The study was discussed in an oral presentation at the Annual Meeting of the American Association for Cancer Research (AACR). According to the study, GX15-070 demonstrated potent single agent activity against ALL blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

In this study, researchers obtained leukemia blast cells from five infants and one child with primary ALL. The blasts were exposed to GX15-070 as a single agent in vitro for three days. In all six cases, GX15-070 exhibited potent single agent activity and IC(50) values were within clinically achievable concentrations. High BCL-2 expression and low expression of particular BH3-only BCL-2 family mRNAs in this disease correlate with GX15-070 sensitivity in vitro.

"GX15-070 is an appropriate candidate for ALL treatment because the imbalanced expression of Bcl-2 family proteins in this cancer leads to impaired apoptosis," said Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "Additionally, this study further upholds what we already have observed about our lead candidate's utility as a single agent and in combination with other therapies."

These data were presented by Dr. Alena Zhang from Dr. Carolyn Felix's laboratory at Children's Hospital of Philadelphia on April 17 at 3:40 PM in an abstract titled, "BCL-2:BH3-only pro-apoptotic gene expression ratios correlate with in vitro sensitivity of primary MLL(+) infant acute lymphoblastic leukemia to small molecule pan-BCL-2 family inhibitor GX15-070."

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1b trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. GX15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.

About Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a fast-growing cancer of the white blood cells, which the body uses to fight infections. The disease is characterized by the bone marrow's overproduction of immature, unformed cells called blasts that would normally develop into mature lymphocytes. These abnormal blasts cannot fight infections, grow quickly, and interfere with normal red blood cells, white blood cells, and platelets. Approximately 4,000 new cases of ALL are diagnosed in the United States each year, and it is fatal if left untreated, because the disease can spread to the bloodstream and organs quickly. It mainly appears in children younger than 10, but one-third of cases are in adults. ALL is the most common form of infant leukemia.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apopt osis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
or
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
dviens@geminx.com


'"/>




Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):